Guggenheim 3rd Annual Healthcare Innovation Conference - SAGIMET BIOSCIENCES INC

Explicit Guidance:

• Capitalization Runway: Raised $175 million in April and an additional $115 million via reverse inquiry to remain well-capitalized through 2028 and through the data readout next year.
• Second Oral Inhibitor Program: Phase 2 program for the second oral fast inhibitor is set to initiate by the end of the current year, with data expected "at about the same time next year" as the primary Phase 3 readout for the lead asset.
• Topical Fast Inhibitor Program: The company aims to advance a topical fast inhibitor through development and into human trials in 2028.
• Phase 3 Readout Timeline: Primary endpoint results for the U.S. Phase 3 study are expected by the end of the next year.

Business-Segment Outlook:

• Dermatology Focus: Strategic pivot to dermatology (acne) continues, targeting a U.S. market of 10–15 million patients with moderate-to-severe acne currently underserved by oral antibiotics or topicals.
• Product Differentiation: The lead asset (Denny/Fasinib) is positioned to replace antibiotic therapy and dramatically reduce topical usage, particularly for truncal acne (affecting >50% of patients) where caregivers are required.
• Treatment Paradigm Shift: Anticipated positioning of Denny as a step-up therapy for IgA 2–4 patients and a mandatory step before Accutane (isotretinoin), aiming for extended use in chronic acne populations (average 10+ years duration).
• Pipeline Potency: The second oral inhibitor is approximately twice as potent as the lead asset; success is defined by either increased efficacy or improved safety tolerability.
• Topical Expansion: A topical fast inhibitor is in formulation development targeting "mild" acne patients, with human trials scheduled for 2028.

Market and Competitive Outlook:

• Market Reception: Management reports "very favorable" market reception and enthusiasm from the dermatology community and Key Opinion Leaders (KOLs) regarding the mechanism of fast inhibition.
• Competitive Displacement: Expectation that the molecule will "dramatically reduce, if not entirely replace" current antibiotic therapies due to the need to curb resistance and the drug's efficacy on sebum production and inflammation.
• Patient Population Expansion: FDA guidance suggests including adolescents (ages 12–17), expanding the addressable market beyond the adult population previously studied by Chinese partners.

Macro / Industry Outlook:

• Regulatory Confidence: The FDA's specific request to include adolescent patients and the cross-referencing of data with the hepatology (MASH) division indicate high regulatory confidence in the molecule's safety profile.
• Treatment Gaps: Industry recognition of the limitations of current antibiotics (resistance, gut biome impact), topicals (irritation, photosensitivity, trunk application difficulty), and Accutane (complex monitoring) creates a structural opportunity for Denny.

Strategic Initiatives:

• Phase 3 Study Execution: U.S. Phase 3 trial initiated with first patient dosed on October 21; enrolling 800 patients (450 adolescents, 350 adults) with 530 intended for open-label extension.
• Site Activation: Enrollment ramp-up ongoing with nearly half of sites activated and new sites added daily; enrollment period estimated at approximately six months.
• Compliance Technology: Implementation of "smart caps" on pill bottles for real-time adherence monitoring for both the Phase 3 trial and the open-label extension (OLE) to mitigate adolescent compliance risks.
• Partnership Leverage: Utilization of existing data from Chinese partner Ascletus (Scletus) regarding Phase 2/3 results (20% IGA improvement) to support U.S. study design and regulatory discussions.

Risks and Headwinds to Outlook:

• Adolescent Compliance: While expected to be rare (<1–2% non-compliance), management acknowledges the potential risk of patient dropouts in adolescent populations and has implemented smart caps to monitor usage.
• Open-Label Attrition: Anticipated 20% loss of patients in the open-label extension due to administrative reasons or life events, which has been factored into study planning.
• Data Uncertainty: Future decisions on the positioning of the second oral inhibitor depend on Phase 2 data readout next year to determine if increased potency translates to superior efficacy or safety.
• Regulatory Labeling: Final label indications and the inclusion of long-term efficacy data from the OLE remain subject to ongoing FDA discussions at the time of filing.

Management Tone on the Future:

• Confidence Level: High; described as a "very nice" alignment of factors leading to a strategic shift, with strong belief that the data "determines" a replacement of current antibiotics.
• Certainty of Outcome: Management states there is "one outcome" for the molecule: it will replace antibiotics and reduce topicals.
• Timeline Adherence: Management expresses confidence in the enrollment timeline (6 months) and the ability to deliver primary data by the end of the next year.

Miscellaneous:

• Safety Profile: Long-term extension data from China showed safety remained consistent with short-term results, with only mild-to-moderate dry skin and dry eye as adverse events (no SAEs or Grade 3 events).
• Rapid Efficacy: Distinct advantage noted where treatment effects are visible after two weeks and significant by four weeks, contrasting with the 12-week lag typical of anti-androgens.